Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Asthma Treatment Market 

5.1. COVID-19 Landscape: Asthma Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Asthma Treatment Market, By Medication

8.1. Asthma Treatment Market, by Medication Type, 2023-2032

8.1.1. Quick-relief medication

8.1.1.1. Market Revenue and Forecast (2021-2032)

8.1.2. Long-term control medication

8.1.2.1. Market Revenue and Forecast (2021-2032)

Chapter 9. Global Asthma Treatment Market, By Route of Administration

9.1. Asthma Treatment Market, by Route of Administration, 2023-2032

9.1.1. Inhalers

9.1.1.1. Market Revenue and Forecast (2021-2032)

9.1.2. Prefilled syringes/vials

9.1.2.1. Market Revenue and Forecast (2021-2032)

9.1.3. Others

9.1.3.1. Market Revenue and Forecast (2021-2032)

Chapter 10. Global Asthma Treatment Market, By Adjunct Therapy 

10.1. Asthma Treatment Market, by Adjunct Therapy, 2023-2032

10.1.1. LAMA (long-acting muscarinic antagonists)

10.1.1.1. Market Revenue and Forecast (2021-2032)

10.1.2. LABA (long-acting beta antagonists)

10.1.2.1. Market Revenue and Forecast (2021-2032)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2021-2032)

Chapter 11. Global Asthma Treatment Market, By Distribution Channel 

11.1. Asthma Treatment Market, by Distribution Channel, 2023-2032

11.1.1. Online pharmacies

11.1.1.1. Market Revenue and Forecast (2021-2032)

11.1.2. Hospital pharmacies

11.1.2.1. Market Revenue and Forecast (2021-2032)

11.1.3. Retail pharmacies & drug stores

11.1.3.1. Market Revenue and Forecast (2021-2032)

Chapter 12. Global Asthma Treatment Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Medication (2021-2032)

12.1.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.1.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Medication (2021-2032)

12.1.5.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.1.5.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Medication (2021-2032)

12.1.6.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.1.6.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Medication (2021-2032)

12.2.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.2.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Medication (2021-2032)

12.2.5.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.2.5.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Medication (2021-2032)

12.2.6.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.2.6.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Medication (2021-2032)

12.2.7.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.2.7.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Medication (2021-2032)

12.2.8.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.2.8.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Medication (2021-2032)

12.3.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.3.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Medication (2021-2032)

12.3.5.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.3.5.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Medication (2021-2032)

12.3.6.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.3.6.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Medication (2021-2032)

12.3.7.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.3.7.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Medication (2021-2032)

12.3.8.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.3.8.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Medication (2021-2032)

12.4.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.4.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Medication (2021-2032)

12.4.5.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.4.5.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Medication (2021-2032)

12.4.6.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.4.6.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Medication (2021-2032)

12.4.7.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.4.7.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Medication (2021-2032)

12.4.8.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.4.8.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Medication (2021-2032)

12.5.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.5.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Medication (2021-2032)

12.5.5.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.5.5.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Medication (2021-2032)

12.5.6.2. Market Revenue and Forecast, by Route of Administration (2021-2032)

12.5.6.3. Market Revenue and Forecast, by Adjunct Therapy (2021-2032)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2032)

Chapter 13. Company Profiles

13.1. AstraZeneca

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Teva Pharmaceutical Industries Ltd.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. GlaxoSmithKline plc

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Boehringer Ingelheim International GmbH

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Roche Holding AG / Novartis AG

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Merck & Co., Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Koninklijke Philips N.V.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Sanofi-Aventis SA

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. MundiPharma

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms